Free practice quiz
BCOP Prep Course (BCOP): free quiz
10 questions from the program. See your score right away, then unlock the explanation of every answer.
- Question 1 of 10
A pharmacist reviews pembrolizumab 200 mg IV every 3 weeks for metastatic non-small cell lung cancer with high PD-L1 expression and no targetable driver alteration on molecular testing. Which tumor-biology concept best explains why an anti-PD-1 strategy may be beneficial in this setting?
Why D is correct
PD-1/PD-L1 is a hallmark-linked immune evasion pathway. Pembrolizumab restores antitumor T-cell activity by blocking PD-1 signaling, which is especially relevant when tumor PD-L1 expression is high and no dominant targetable driver directs an alternative class choice.
Pharmacist Action: NOTICE high PD-L1 expression and lack of targetable driver mutation; SAY checkpoint blockade is being used to counter tumor immune evasion; MONITOR for immune-related toxicities and response at each cycle; HOLD/CLARIFY/ESCALATE for suspected grade 2 or higher immune-mediated adverse events or if biomarker data are incomplete.Why C is incorrect
This is tempting because angiogenesis is another hallmark of cancer. The eliminating fact is that pembrolizumab does not inhibit VEGF signaling; VEGF-targeted benefit is associated with antiangiogenic agents, not PD-1 antibodies.
Pharmacist Action: NOTICE confusion between immunotherapy and antiangiogenic classes; SAY mechanism-based class selection matters; MONITOR regimen-drug match during verification; HOLD/CLARIFY/ESCALATE if the stated rationale for use does not match the ordered agent.Why A is incorrect
This is tempting because genomic instability contributes to tumor evolution and can affect treatment sensitivity. The eliminating fact is that genomic instability does not exist solely to enhance chemotherapy sensitivity; its more relevant link here is neoantigen generation and variable immunogenicity, not a direct PD-1 mechanism.
Pharmacist Action: NOTICE oversimplified biology claims; SAY genomic instability may influence resistance and antigenicity rather than guarantee chemo sensitivity; MONITOR biomarker context with each line of therapy; HOLD/CLARIFY/ESCALATE if treatment selection is based on inaccurate molecular interpretation.Why B is incorrect
This is tempting because EGFR is an important driver in a subset of NSCLC. The eliminating fact is that EGFR signaling is not universally activated, and pembrolizumab does not work by inhibiting receptor tyrosine kinases; EGFR-directed therapy requires a confirmed driver alteration.
Pharmacist Action: NOTICE whether driver testing is documented before immunotherapy verification; SAY targeted therapy depends on biomarker confirmation; MONITOR molecular results and sequence-of-therapy issues; HOLD/CLARIFY/ESCALATE if a potentially targetable alteration has not been reconciled with the treatment plan. - Question 2 of 10
An oncology pharmacist is prioritizing same-day review of several new treatment starts. Which patient factor from the selected topic most directly supports urgent pharmacist attention?
A. This is correct because the node states that tumor burden and proliferative rate affect urgency and supportive care needs.
B. This is incorrect because the topic emphasizes not just cancer type labels but growth patterns, kinetics, tumor burden, and treatment logic.
C. This is incorrect because the source pack specifically identifies higher burden and rapid proliferation as drivers of urgency; this option removes those factors.
D. This is incorrect because cell-cycle kinetics can influence schedule dependence, so timing should not automatically be assumed irrelevant.
- Question 3 of 10
A tumor board case describes progression after a targeted regimen. The tumor still depends on growth signaling, but the original inhibited pathway is no longer the only route maintaining malignant behavior. Which mechanism is most consistent with this scenario?
A. Bypass signaling is correct because the source pack lists it as a resistance mechanism, and the scenario describes continued malignant signaling through routes outside the originally inhibited pathway.
B. Drug efflux is incorrect because the case does not describe reduced intracellular drug exposure.
C. Repair pathway activation is incorrect because the case does not focus on repair of treatment-induced damage.
D. Treatment pressure absence is incorrect because the scenario involves progression after targeted therapy, and the source pack emphasizes prior exposure and treatment pressure as drivers of acquired resistance.
- Question 4 of 10
A pharmacist is reviewing a proposed targeted therapy. The report clearly identifies a point mutation, but the treatment plan does not state the tumor type or assay validity. What is the best interpretation?
A. This is correct because the node requires both differentiating alteration types and determining actionability based on tumor type and assay validity.
B. This is incorrect because the source pack warns against overgeneralization and states that tumor type affects actionability.
C. This is incorrect because point mutation and amplification are distinct alteration categories.
D. This is incorrect because assay validity is explicitly listed as a determinant of actionability.
- Question 5 of 10
Which statement best summarizes why NGS assay limits are tested in a BCOP-style QBank?
A. This is correct because the node connects NGS assay characteristics, specimen adequacy, ctDNA limitations, and variant interpretation to pharmacist verification of biomarker-supported targeted therapy.
B. This is incorrect because pharmacist scope in the course context is medication expertise and verification, not performing biopsy procedures.
C. This is incorrect because NGS assay limits do not replace biomarker interpretation; they are part of interpreting whether results are reliable and actionable.
D. This is incorrect because the source pack explicitly connects assay limits to treatment verification and medication safety, not billing alone.
- Question 6 of 10
A BCOP-style item stem provides details indicating that a patient is not in an average-risk screening group. What should the examinee do with that information?
A. This is incorrect because the node explicitly identifies average-risk versus elevated-risk frameworks as a high-yield distinction.
B. This is correct because the selected node says to distinguish average-risk versus elevated-risk frameworks when provided in the stem.
C. This is incorrect because applying the same approach regardless of risk conflicts with the required distinction in the source pack.
D. This is incorrect because the selected node is about screening and early detection, not assuming pharmacogenomics testing from risk status alone.
- Question 7 of 10
A patient says, "I found a supplement online that claims to prevent cancer. Can you approve this as my prevention plan?" Based on the selected source pack, which pharmacist response is most appropriate?
A. This is incorrect because the source pack supports guideline-based counseling and referral, not endorsement of unsupported prevention claims as a complete plan.
B. This is correct because the node emphasizes prevention counseling within appropriate scope and guideline-based referral. It supports counseling on risk-reduction principles rather than overstepping or approving unsupported claims.
C. This is incorrect because cancer prevention and risk reduction are explicit blueprint and node topics for oncology pharmacy counseling.
D. This is incorrect because diagnosing hereditary risk would exceed the pharmacist's scope as framed by the selected node.
- Question 8 of 10
Which pharmacist action most directly supports the blueprint area of patient and caregiver education within therapeutic implementation?
A: This is correct because the source pack connects support and education resources with patient and caregiver education, health literacy, access barriers, and caregiver support needs.
B: This is incorrect because clinical trial endpoints fall under research and trial design, not direct patient and caregiver education.
C: This is incorrect because sequencing interpretation relates to oncology testing and genomics, not the selected support and education node.
D: This is incorrect because hazardous medication disposal is a practice management concept, not the specific patient and caregiver education action described.
- Question 9 of 10
A patient is eligible for a biomarker-directed therapy in the current disease setting. The pharmacist notes that the patient previously received a regimen with substantial cumulative toxicity affecting the same organ system that the new regimen may worsen. Which concept best explains why this history matters for later-line selection?
A. Correct. The node states that biomarker status and cumulative toxicity alter later-line options. Even when a biomarker supports a therapy, the pharmacist must consider prior toxicity burden when assessing appropriateness.
B. Incorrect. The source specifically connects cumulative toxicity to later-line options, not only initial therapy.
C. Incorrect. Biomarker status is important, but it does not replace review of prior exposure, refractory status, relapse interval, or cumulative toxicity.
D. Incorrect. Patient-centered care is important, but the supplied line-of-therapy framework requires disease setting, biomarker status, prior history, and toxicity considerations rather than preference alone.
- Question 10 of 10
A prescriber enters an oncology regimen with an abbreviated schedule. The pharmacist cannot determine whether the schedule is based on an approved protocol, a local pathway, or an intentional individualized adjustment. Which action best supports safe verification?
A. This is incorrect because unsupported schedule details are specifically listed in the source pack as requiring clarification. Schedule differences can affect regimen concordance and safety.
B. This is correct because the pharmacist should clarify unsupported schedule issues and confirm protocol details when pathways may vary. This is the safest action before verification.
C. This is incorrect because the source pack supports clarification rather than automatic cancellation. The schedule may be intentional, but the rationale must be confirmed.
D. This is incorrect because regimen verification should occur before administration. The source pack places responsibility on pharmacist medication safety action and team clarification, not delegation of regimen selection decisions to nursing at administration.
See why each answer is right or wrong
Enter your email to unlock the explanation of every question, free.